Treatment success in patients requiring treatment change from olanzapine to risperidone long acting injectable (TRESOR)

Trial Profile

Treatment success in patients requiring treatment change from olanzapine to risperidone long acting injectable (TRESOR)

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2012

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms TRESOR
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 27 Apr 2010 Actual number of patients (99) added as reported by ClinicalTrials.gov record.
    • 27 Apr 2010 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov record.
    • 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top